伊莎妥昔单抗治疗多发性骨髓瘤的研究进展  

Research progress on treatment of multiple myeloma with isatuximab-irfc

作　　者：刘燕[1] 陶洁 Liu Yan;Tao Jie(Graduate School,Shanxi Medical University,Taiyuan 030000,Shanxi Province,China;Department of Hematology,First Hospital of Shanxi Medical University,Taiyuan 030000,Shanxi Province,China)

机构地区：[1]山西医科大学研究生院,太原030000 [2]山西医科大学第一临床医学院血液科,太原030000

出　　处：《国际输血及血液学杂志》2020年第6期538-542,共5页International Journal of Blood Transfusion and Hematology

摘　　要：多发性骨髓瘤(MM)是一种以浆细胞恶性增殖,并通过分泌大量功能缺陷的免疫球蛋白(Ig)及其片段,同时抑制正常浆细胞增殖及Ig分泌,进而造成相关组织或器官损伤的血液系统恶性疾病。伊莎妥昔单抗是一种人工合成,可与IgG1嵌合的新型单克隆抗体药物,其与MM细胞表面的CD38受体结合后,进而通过多种机制诱导MM细胞凋亡。目前,伊莎妥昔单抗主要用于复发/难治性MM(RRMM)的治疗。笔者从伊莎妥昔单抗治疗MM的作用机制、临床疗效及药物不良反应等方面的研究新进展进行阐述。Multiple myeloma(MM)is a hematological malignancies with plasma cell malignant proliferation,which inhibits the proliferation of normal plasma cells and the secretion of immunoglobulin(Ig)by secreting a large number of Ig and its fragments with defective functions,thus causing injury to relevant organs or tissues.Isatuximab-irfc(sarclisa)is a novel synthetic monoclonal antibody that chimeric with IgG1,which can bind to the CD38 receptor on MM cells and induce MM cell apoptosis through various mechanisms.Isetuximab-irfc is currently used for the treatment of relapsed/refractory MM(RRMM).This review elaborates on the advances in the mechanisms,clinical efficacy and adverse reactions of isatuximab-irfc in the treatment of MM.

关 键 词：多发性骨髓瘤 抗体 单克隆 伊莎妥昔单抗 药物疗法 抗原 CD38 

分 类 号：R733.3[医药卫生—肿瘤]